Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Catalyst Pharmaceuticals (CPRX) over the last 14 years, with Sep 2025 value amounting to $32.4 million.

  • Catalyst Pharmaceuticals' Free Cash Flow fell 55.33% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $234.5 million, marking a year-over-year increase of 4.70%. This contributed to the annual value of $239.3 million for FY2024, which is 66.88% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Free Cash Flow of $32.4 million as of Q3 2025, which was down 54.49% from $71.3 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Free Cash Flow high stood at $72.6 million for Q3 2024, and its period low was $2.9 million during Q1 2021.
  • Moreover, its 3-year median value for Free Cash Flow was $55.6 million (2023), whereas its average is $49.7 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 59.75% in 2021, then spiked by 192.04% in 2022.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Free Cash Flow stood at $19.1 million in 2021, then soared by 109.44% to $40.1 million in 2022, then skyrocketed by 38.62% to $55.6 million in 2023, then rose by 27.42% to $70.8 million in 2024, then tumbled by 55.33% to $32.4 million in 2025.
  • Its Free Cash Flow was $32.4 million in Q3 2025, compared to $71.3 million in Q2 2025 and $60.0 million in Q1 2025.